
    
      The REPEAT-study is a prospective, multicenter, non-randomized phase 1 and phase 2 study in
      which we evaluate the effect of lenalidomide, cyclophosphamide and prednisone (REP-therapy)
      in patients with relapsed multiple myeloma, previously treated with lenalidomide and
      refractory to lenalidomide monotherapy.
    
  